Implications of all the available evidence
METASTATIC PROSTATE CANCER
The current study provides robust clinical support for the immunogenic effect of radiation and provides the impetus to further evaluate immune checkpoint inhibition in patients with metastatic prostate cancer as a maintenance treatment following priming with targeted radioligand therapy. The ability to re-treat with lutetium-177 [